FDL169 ( DrugBank: FDL169 )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
299嚢胞性線維症8

299. 嚢胞性線維症


臨床試験数 : 1,695 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03756922
(ClinicalTrials.gov)
November 27, 201827/11/2018A DDI Study of FDL169 and FDL176 in Healthy SubjectsA Phase 1/2, Drug-Drug Interaction Study of FDL169 and FDL176 in Healthy Subjects and in Cystic Fibrosis Subjects Homozygous for the F508del-CFTR MutationCystic FibrosisDrug: FDL169;Drug: FDL176Flatley Discovery Lab LLCNULLSuspended18 Years55 YearsAll78Phase 1/Phase 2United Kingdom
2NCT03527095
(ClinicalTrials.gov)
April 5, 20184/5/2018A Study to Compare the Pharmacokinetics of Different Oral Formulations of FDL169 in Healthy SubjectsA Phase 1, Open-label, Randomised, Cross Over Study to Compare the Pharmacokinetics of Different Oral Formulations of FDL169 in Healthy Subjects Following Single DosesCystic FibrosisDrug: FDL169Flatley Discovery Lab LLCNULLCompleted18 Years55 YearsAll11Phase 1United Kingdom
3NCT03516331
(ClinicalTrials.gov)
March 7, 201824/4/2018A Drug-Drug Interaction Study of FDL169 and FDL176 in Healthy SubjectsA Phase 1, Open Label, Drug-Drug Interaction Study of FDL169 and FDL176 in Healthy SubjectsCystic FibrosisDrug: FDL176 & FDL169 coadministrationFlatley Discovery Lab LLCNULLCompleted18 Years55 YearsAll16Phase 1United Kingdom
4NCT03424252
(ClinicalTrials.gov)
December 18, 201731/1/2018An Phase 1 Study to Evaluate the Pharmacokinetic (PK) Profile of FDL169 New Formulations in Healthy SubjectsA Phase 1, Open-label, Crossover, Randomised Study to Evaluate the Pharmacokinetic Profile of FDL169 Sublingual Formulations in the Fed State in Healthy SubjectsCystic FibrosisDrug: FDL169Flatley Discovery Lab LLCNULLCompleted18 Years55 YearsAll11Phase 1United Kingdom
5NCT03093714
(ClinicalTrials.gov)
August 23, 201716/3/2017A Study to Evaluate Safety, PK and PD of FDL169 in Cystic Fibrosis SubjectsA Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate Safety, Pharmacokinetics (PK) and Pharmacodynamics(PD) of FDL169 in Cystic Fibrosis (CF) Subjects Homozygous for the F508del-CFTR MutationCystic FibrosisDrug: FDL169;Drug: PlaceboFlatley Discovery Lab LLCNULLCompleted18 Years85 YearsAll27Phase 1Australia;Czechia;Germany;United Kingdom
6NCT02767297
(ClinicalTrials.gov)
April 20165/5/2016Bioavailability and Pharmacokinetics Study of FDL169 in Healthy Subjects and Subjects With Cystic FibrosisA Three-Part Phase 1b Bioavailability and Pharmacokinetics Study of Two Formulations of FDL169 in Healthy Subjects and Subjects With Cystic FibrosisCystic FibrosisDrug: FDL169Flatley Discovery Lab LLCNULLCompleted18 YearsN/ABoth46Phase 1/Phase 2United Kingdom
7NCT02680418
(ClinicalTrials.gov)
December 20152/2/2016Pharmacokinetics of FDL169 in Healthy Female SubjectsA Phase I Dose Escalation Study to Assess the Pharmacokinetics (PK) of FDL169 in Healthy Female VolunteersCystic FibrosisDrug: FDL169Flatley Discovery Lab LLCNULLCompleted18 Years55 YearsFemale8Phase 1United Kingdom
8NCT02359357
(ClinicalTrials.gov)
January 201513/1/2015FTIH - Single and Repeat Oral Doses of FDL169 in Healthy VolunteersA Phase 1, Randomised, Double-Blind, Placebo-Controlled, Dose-Escalation First-Time-in-Human Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of Single and Repeat Oral Doses of FDL169 in Healthy VolunteersCystic FibrosisDrug: FDL169;Drug: PlaceboFlatley Discovery Lab LLCNULLCompleted18 Years45 YearsMale130Phase 1United Kingdom